Diabetes drug may have role in prevention of glaucoma, finds Study
USA: The use of glucagon-like peptide 1 receptor (GLP-1R) agonist significantly lowers hazard reduction for a new diagnosis of glaucoma.
The findings, published in the British Journal of Ophthalmology, support the use of glucagon-like peptide 1 receptor (GLP-1R) agonists in glaucoma prevention.
glucagon-like peptide 1 receptor (GLP-1R) agonists regulate blood sugar levels and are commonly used for the treatment of type 2 diabetes (T2D). Recent studies have shown treatment with the glucagon-like peptide 1 receptor (GLP-1R) agonist NLY01 to be associated with decreased retinal neuroinflammation and glial activation to rescue retinal ganglion cells in a mouse model of glaucoma.
Against the above background, Brian L VanderBeek, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA, and colleagues aimed to examine whether GLP-1R agonist exposure impacts glaucoma risk using an insurance claims database.
A retrospective cohort of patients who initiated a new GLP-1R agonist was 1:3 age, gender, race, classes of active diabetes medications, and year of index date matched to patients who initiated a different class of oral diabetic medication. To test the association between GLP-1R agonist exposure and a new diagnosis of primary open-angle glaucoma, glaucoma suspect, or low-tension glaucoma, inverse probability of treatment weighting (IPTW) was used within a multivariable Cox proportional hazard regression model.
Cohorts were comprised of 1961 new users of GLP-1R agonists matched to 4371 unexposed controls.
The study yielded the following findings:
- After IPTW, all variables were balanced (standard mean deviation <|0.1|) between cohorts.
- Ten (0.51%) new diagnoses of glaucoma were present in the GLP-1R agonist cohort compared with 58 (1.33%) in the unexposed controls.
- After adjustment, GLP-1R exposure conferred a reduced hazard of 0.56, suggesting that GLP-1R agonists decrease the risk for glaucoma.
"The use of GLP-1R agonist was associated with a statistically significant hazard reduction for a new diagnosis of glaucoma," wrote the authors. "Our findings support further investigations into the use of GLP-1R agonists in glaucoma prevention."
Reference:
The study titled, "Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma," is published in the British Journal of Ophthalmology.
DOI: https://bjo.bmj.com/content/early/2021/08/18/bjophthalmol-2021-319232
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.